1	Using polygenic risk scores for prioritising individuals at greatest need
2	of a CVD risk assessment
3	
4	Ryan Chung ^{1,2} , Zhe Xu ^{1,2} , Matthew Arnold ^{1,2} , Samantha Ip ^{1,2,3} , Hannah Harrison ³ , Jessica
5	Barrett ⁴ , Lisa Pennells ^{1,2} , Lois G. Kim ^{1,2,5} , Emanuele DiAngelantonio ^{1,2,5,6,7,8} , Ellie Paige ^{9,10} ,
6	Scott C. Ritchie ^{1,2,6,11} , Michael Inouye ^{1,2,6,7,10,12} , Juliet A. Usher-Smith ¹³ , Angela M.
7	Wood*1,2,5,6,7,14
8 9	¹ British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health
10	and Primary Care, University of Cambridge, Cambridge, UK
11	² Heart and Lung Research Institute, University of Cambridge, Cambridge, UK
12	³ Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care,
13	University of Cambridge, Cambridge, UK
14	⁴ Medical Research Council Biostatistics Unit, University of Cambridge, Cambridge, UK
15	⁵ National Institute for Health and Care Research Blood and Transplant Research Unit in
16	Donor Health and Behaviour, University of Cambridge, Cambridge, UK
17	⁶ British Heart Foundation Centre of Research Excellence, University of Cambridge,
18	Cambridge, UK
19	⁷ Health Data Research UK Cambridge, Wellcome Genome Campus and University of
20	Cambridge, Cambridge, UK
21	⁸ Health Data Science Research Centre, Human Technopole, Milan, Italy 20157
22	⁹ National Centre for Epidemiology and Population Health, Australian National University,
23	Canberra, Australia
24	¹⁰ The George Institute for Global Health, UNSW Sydney, Australia
25	¹¹ Cambridge Baker Systems Genomics Initiative, Department of Public Health and Primary
26	Care, University of Cambridge, Cambridge, UK
27	¹² Cambridge Baker Systems Genomics Initiative, Baker Heart and Diabetes Institute,
28	Melbourne, Victoria, Australia
29 30	¹³ Primary Care Unit, Department of Public Health and Primary Care, University of NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. Cambridge, Cambridge, UK

31 ¹⁴ Cambridge Centre of Artificial Intelligence in Medicine 32 33 *Corresponding author: amw79@medschl.cam.ac.uk, Cardiovascular Epidemiology Unit, 34 Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK 35 36 Abstract Word count = 283 37 Manuscript Word count = 4547 38 4 Main tables 39 40 2 Main figures 41 42 **Supplementary Material** 43 **16 Supplementary Tables** 44 **6** Supplementary Figures 45 Web Appendix 1-3

47 **ABSTRACT**

48

Background: To provide quantitative evidence of the use of polygenic risk scores (PRS) for
systematically identifying individuals for invitation for full formal cardiovascular disease
(CVD) risk assessment.

52 53

61

54 **Methods:** 108,685 participants aged 40-69, with measured biomarkers, linked primary care 55 records and genetic data in UK Biobank were used for model derivation and population 56 health modelling. Prioritisation tools using age, PRS for coronary artery disease and stroke, 57 and conventional risk factors for CVD available within longitudinal primary care records 58 were derived using sex-specific Cox models. Rescaling to account for the healthy cohort 59 effect, we modelled the implications of initiating guideline-recommended statin therapy 60 after prioritising individuals for invitation to a formal CVD risk assessment.

Results: 1,838 CVD events were observed over median follow up of 8.2 years. If primary care records were used to prioritise individuals for formal risk assessment using age- and sex-specific thresholds corresponding to 5% false negative rates then we would capture 65% and 43% events amongst men and women respectively. The numbers of men and women needed to be screened to prevent one CVD event (NNS) are 74 and 140 respectively. In contrast, adding PRS to both prioritisation and formal assessments, and selecting thresholds to capture the same number of events resulted in a NNS of 60 for men and 90 for women.

Conclusion: The use of PRS together with primary care records to prioritise individuals at
 highest risk of a CVD event for a formal CVD risk assessment can more efficiently prioritise

those who need interventions the most than using primary care records alone. This could

73 lead to better allocation of resources by reducing the number of formal risk assessments in

74 primary care while still preventing the same number CVD events.

75

76

INTRODUCTION 78

79

Cardiovascular disease (CVD) remains a major cause of morbidity and mortality worldwide.¹ 80 Identifying individuals at a high risk of CVD in order to manage and implement interventions 81 to reduce risk of CVD remains an important aim.^{2,3} Prediction tools utilising the risk factor 82 levels of individuals to estimate a 5 or 10 year risk of CVD have been developed to aid 83 clinical decision making and are recommended by healthcare guidelines across the world.^{3–} 84 85 ¹⁰ However, recent studies have debated the clinical value and cost effectiveness of national risk assessment programmes.^{11–17} In line with this, recent guidelines have made 86 recommendations to better utilise existing primary care records to improve the 87 stratification of high-risk individuals prior to formal CVD risk assessments¹⁸. However, few 88 89 strategies or tools to systematically identify such individuals have been recommended. 90 Proposals have also been recommended to prioritise individuals using CVD-based polygenic 91 risk scores (PRS); such PRS have been shown to be independent of other CVD risk factors, 92 offering improved stratification with high concordance between categories of polygenic risk 93 and future CVD risk across the life course, and to improve discriminatory performance when used to supplement existing CVD risk scores.^{19–21}. However, no studies have quantified the 94 impact PRS would have for prioritisation. 95

96

Therefore, to investigate the benefits of PRS to systematically prioritise individuals at high 97 98 risk of CVD, we compare systematically prioritising individuals using a PRS based 99 prioritisation tool against current guidelines recommendations of using a prioritisation tool 100 based on longitudinal primary care records.^{22–26}

- 101
- 102
- 103

104 **METHODS**

105

106 UK Biobank data source

107 Data from UK Biobank (UKB) were used to derive each CVD risk tool (prioritisation and formal assessment) and to model the implications of prioritising individuals for formal 108 assessment. UKB is a prospective cohort study with detailed baseline information, genetic 109 110 data and linked primary care record data available for 177,359 individuals in England 111 recruited between 2006 and 2010²⁷. Genetic data was sequenced using a genome wide 112 array of approximately 826,000 markers with imputation to approximately 96 million markers.²⁷ Primary care data was provided from the The Phoenix Partnership, Egton Medical 113 Information Systems and Vision GP system suppliers²⁸. Data were linked with secondary 114 115 care admissions from Hospital Episode Statistics (HES) and mortality records from the Office for National Statistics (ONS). For this study, primary care records were restricted to those 116 measured between the 1st April 2004, the introduction of the Quality and Outcomes 117 Framework (QOF) and UKB baseline survey. To assess the impact of PRS as a prioritisation 118 119 tool and compare with primary care records, analysis was restricted to individuals with 120 complete genetic data necessary for calculating the PRS, at least one primary care record 121 before baseline survey and without prior CVD or statin initiation. Individuals contributing to 122 the PRS derivation were also excluded.

123

124 **CPRD data source**

Data from the Clinical Practice Research Datalink (CPRD) were used for estimating the average risk factor values and rescaling of 10-year risks (described in later sections.) The CPRD database is a large UK primary care database containing primary care records²⁸ with linked information from HES and mortality records from the ONS. The most recent 5 years available primary care records were extracted for 870,486 individuals who were still alive and without prior CVD on the 1st January 2014 and had no statins throughout follow-up until 31st May 2019, the end of data availability **(Supplementary figure 1).**

133 Outcomes

CVD was defined as the first ever incident of fatal or non-fatal events of coronary heart 134 135 disease (including angina and myocardial infarction) ischaemic heart disease and stroke 136 (code lists provided in **Supplementary table 1**), appearing in the linked HES and ONS 137 databases during follow up.

138

Risk factors 139

Two PRS for coronary artery disease (CAD) and stroke, constructed using a meta-score 140 approach and external summary statistics from large genome wide association studies^{20,29}, 141 142 were used as independent variables. Conventional risk factors (as those in the QRISK2 143 scores⁴) were selected: age, sex, ethnicity, Townsend score, smoking status (current 144 smoker), history of diabetes (type 1 or type 2 or history of diabetes medication), family 145 history of CVD, history of chronic kidney disease (stages 4 and 5), history of atrial fibrillation 146 status, history of blood pressure treatment, history of rheumatoid arthritis, total and high 147 density lipoprotein (HDL) cholesterol, systolic blood pressure (SBP), body mass index (BMI), and age interactions with Townsend score, history of diabetes, family history of CVD, history 148 149 of atrial fibrillation, history of blood pressure treatment, SBP and BMI.

150

151 Statistical modelling

Sex-specific Cox models were used to derive three different prioritisation tools for 152 153 estimating 10-year CVD prioritisation risk. First, we derived a prioritisation tool with linear predictors of baseline age, CAD PRS²⁰ and stroke PRS²⁹. Age interactions were considered 154 but were not statistically significant at the 5% level. Second, we derived a prioritisation tool 155 156 with predictors utilising longitudinal primary care records. To handle missing values, the tool 157 was derived in two stages: in the first stage, we used sex-specific multivariate mixed effects regression models on longitudinal risk factor measurements for SBP, total and HDL 158 159 cholesterol and BMI to estimate current risk factor values (Web appendix 1); in the second stage, we derived sex-specific Cox models with the estimated current risk factor values for 160 SBP, total and HDL cholesterol and BMI, and the most recent primary care measurements 161 for the remaining QRISK2 risk factors. Third, we derived a prioritisation tool with both PRS 162 and primary care records, using the two-stage approach described above with the addition 163 164 of linear predictors for the CAD PRS and stroke PRS in the second stage Cox models. For

165 each of these three tools, the model is used to identify individuals crossing a minimum 10-166 year risk threshold to be invited for a formal assessment.

167

Sex-specific Cox models were used to derive two formal risk assessment models for predicting 10-year formal assessment CVD risk using risk factor measurements observed at UKB baseline survey. First, we re-derived a model based on QRISK2 predictors and second, we derived a model based on QRISK2 predictors enhanced with the CAD PRS and stroke PRS.

All models were validated using 10-fold cross validation and prognostic ability was
quantified using Harrell's C-index to measure discrimination and the net reclassification
improvement (NRI).

176

177 Population Health Modelling

178 Population health modelling was conducted to compare the population health impact of 1) 179 prioritising using a primary care records-based tool followed by a formal assessment with 180 conventional risk factors, 2) prioritising using a PRS and age-based tool followed by a formal 181 assessment with conventional risk factors and PRS and 3) prioritising using both PRS and 182 primary care records, followed by a formal assessment with conventional risk factors and 183 PRS. (Figure 1). Due to UKB being a cohort of healthier individuals than the UK primary care population, we rescaled all estimated 10-year CVD risks so that the distribution of risks 184 185 estimated were using age-group- and sex- specific level risk factors obtained from CPRD and the published QRISK2 score to better reflect CVD risk assessment programme in the general 186 187 population. (Web appendix 2, supplementary table 2). Details of the rescaling method has 188 been described elsewhere.^{30,31}

189

A hypothetical population of 100,000 individuals (50,000 men and women) from the United Kingdom was created; the population age structure was obtained using data from the ONS in 2015³² and the number of expected CVD events was calculated using age-group and sexspecific incidence rates from CPRD (**Supplementary table 3**). A policy of statin initiation for individuals at \geq 10% predicted 10-year formal assessment CVD risk as currently recommended by National Institute for Health and Care Excellence (NICE) guidelines and a 20% reduction in CVD risk were assumed.^{33,34} The population health impact for each of the

197 three prioritisation tools was modelled using age- and sex-specific prioritisation thresholds 198 in two ways. First, we selected prioritisation thresholds to limit the formal CVD risk 199 assessment false negative rate to 5%. Second, we selected prioritisation thresholds for the 200 PRS based prioritisation tools to identify the same number of events that would have been 201 identified if prioritising with primary care records only (with prioritisation thresholds 202 corresponding to 5% false negative rates). We determined the thresholds by varying the 203 false negative rates and chose the rate that best matched the number of events identified.

204

Summary metrics were estimated for: the number needed to screen (NNS) to prevent one CVD event, the number of CVD events identified and the number needed to invite (NNI) to prevent one CVD event. We assumed 100% statin compliance and a 50% invitation uptake of a formal assessment if inviting all individuals^{35,36}. We further assumed an increased invitation uptake of 55% if individuals were prioritised for an invitation to a formal assessment.

211

In sensitivity analyses, we repeated population-health analyses including all individuals, including those without a primary care record for any one of SBP, HDL, total cholesterol or BMI, where those without a record were all invited for formal assessment **(Supplementary table 3).** We also repeated analyses assuming that only 50% of individuals treated with statins were compliant with treatment.

217

Analyses were conducted in R x64 3.6.1 (R Foundation for Statistical Computing, Vienna,

219 Austria). This study follows the RECORD statement (Web Appendix 3)³⁷

221 **RESULTS**

222

223 **Population characteristics**

For our primary analysis, we identified a subset of 108,685 (60%) individuals in UKB with genetic data and a primary care record for at least one of SBP, HDL, total cholesterol and BMI, necessary for the in-person comparison of using either polygenic risk scores or primary care records as a prioritisation method **(Supplementary figure 2).** All individuals had complete information for the conventional risk factors necessary to calculate a 10-year formal CVD risk at baseline survey.

230

231 The mean age at baseline was 56.2 years (SD 8.0) for men and 56.1 years (SD 7.8) for women. During mean of follow-up of 8.2 years, there were 1,838 incident cardiovascular 232 233 events (Table 1). Compared to the measurements observed at the UKB baseline survey, the 234 measurements recorded in primary care records were lower for SBP and total cholesterol and although similar for current smoking status and history of diabetes, were less 235 236 concordant for the remaining disease statuses. The mean time between the first available 237 primary care record and baseline survey was 3.8 years (95% CI: 2.3, 4.5) for men and 3.8 238 years (95% CI: 2.8, 4.7) for women.

239

240 Model performance and comparison

Hazard ratios (HRs) in the prioritisation tools and formal assessment models, for the same predictors, were similar **(Supplementary table 4-5).** HRs for the CAD and stroke PRS were higher among men than in women and remained consistent with and without the inclusion of conventional risk factors.

245

All models had good discriminatory performance with higher performance in women. The Cindex for the PRS + age prioritisation tool in men (C-index = 0.663, 95% CI: 0.649, 0.678) was slightly lower than the primary care records prioritisation tool (C-index = 0.684, 95% CI: 0.670, 0.699) **(Table 2)**, however the difference in performance was greater in women. The greatest discriminatory performance was observed in the model using both conventional risk factors with PRS in both men (C-index = 0.716, 95% CI: 0.702, 0.730) and in women (Cindex = 0.742, 95% CI: 0.722, 0.762). Using conventional risk factors with PRS also improved

the classification of high and low risk individuals compared to using conventional risk factors
only in both men (NRI = 0.0262, 95% CI: 0.0072, 0.0458) and in women (NRI = 0.0265, 95%
CI: 0.0065, 0.0502) (Supplementary table 6).

256

257 The estimated 10-year risks between the primary care records only prioritisation tool and 258 the formal assessment model using conventional risk factors were highly correlated 259 (correlation coefficient = 0.75 for men and 0.80 for women). In contrast, the estimated 10-260 year risks between the PRS + age prioritisation tool and the formal assessment model using 261 conventional risk factors and PRS were less highly correlated (correlation coefficients = 0.67 262 for men and women), and the estimated 10-year risks between the PRS and primary care 263 records based prioritisation tool and the formal assessment model using conventional risk 264 factors with PRS were more highly correlated (correlation coefficients = 0.82 for men and 265 women) (Table 3). Rescaled 10-year risk estimates between all models were similar 266 (Supplementary figure 3).

267

268 **Population health modelling**

269 In a representative population of 100,000 individuals aged 40 to 69, we estimated that there 270 would be 3,573 men and 1,808 women who would experience a CVD event over the next 10 271 years. If conventional risk factors were used as a formal risk assessment model on the whole 272 population, then 2,426 (67.9%) of those men and 801 (44.3%) of those women would have 273 been identified as being at high risk, i.e. conventional risk factors ≥ 10% 10-year CVD risk 274 (Figure 2, supplementary table 7). Assuming 50% of individuals accepted the invitation for a 275 formal assessment and statin therapy would be initiated on all individuals with a 10-year 276 formal CVD assessment risk greater than 10%, and no other preventive interventions 277 implemented, the NNS to prevent one CVD event in men and women would be 103 (95% CI: 100, 107) and 312 (95% CI: 288, 334), and the NNI to prevent one CVD event in men and 278 279 women would be 206 (95% CI: 199, 213) and 624 (95% CI: 576, 668) respectively.

280

If the primary care records-based prioritisation tool, using age- and sex-specific prioritisation thresholds corresponding to 5% false negative rates, was used to prioritise formal assessment (with conventional risk factors) in the population, then 2,335 (65.3%) men and 785 (43.4%) women with CVD events over the next 10 years would be classified at

285 high risk (Figure 2, supplementary table 7). The NNS to prevent one event would reduce to 74 (95% CI: 72, 77) in men and 140 (95% CI: 130, 150) in women (28.2% and 55.1% 286 287 reduction respectively). The NNI to prevent one event would be 135 (95% CI: 130, 141) in 288 men and 255 (95% CI: 235, 274) in women (34.5% and 59.1% reduction respectively)

289

If conventional risk factors enhanced with PRS was used as a formal risk assessment model 290 291 on the whole population, then 2,457 (68.8%) of those men and 844 (46.7%) of those women 292 would have been identified as being at high risk (Figure 2, supplementary table 8). The NNS 293 to prevent one CVD event in men and women would be 102 (95% CI: 98, 106) and 296 (95% 294 CI: 273, 315), and the NNI to prevent one CVD event in men and women would be 204 (95% 295 CI: 197, 211) and 592 (95% CI: 545, 631) respectively.

296

297 If the PRS + age prioritisation tool, using age- and sex-specific prioritisation thresholds 298 corresponding to 5% false negative rates, was used to prioritise formal risk assessment (with 299 the same conventional risk factors with PRS) in the population, then 78.8% of men and 300 74.8% of women would be prioritised and, amongst them, 2,356 (65.9%) men and 813 301 (45.0%) women with CVD events over the next 10 years would be classified at high risk 302 (Figure 2, supplementary table 8). This equates to a 3.7%-4.1% reduction compared to a 303 formal risk assessment using conventional risk factors with PRS on the whole population. 304 However, the NNS to prevent one event would also reduce to 84 (95% CI: 61, 66) in men 305 and 230 (95% CI: 117, 136) in women (17.8% and 22.4% reduction respectively). The NNI to 306 prevent one event would be 152 (95% CI: 146, 158) in men and 418 (95% CI: 384, 447) in 307 women (25.5% and 29.4% reduction respectively).

308

309 If the PRS and primary care records-based prioritisation tool, using age- and sex-specific 310 prioritisation thresholds corresponding to 5% false negative rates, was used to prioritise formal assessment (with conventional risk factors with PRS) in the population, then 2,367 311 (66.3%) men and 825 (45.6%) women would be classified as high risk. (Figure 2, 312 Supplementary table 9). The NNS to prevent one event would reduce to 63 (95% CI: 60, 66) 313 in men and 127 (95% CI: 117, 136) in women (38.2% and 57.1% reduction respectively). The 314 315 NNI to prevent one event would be 115 (95% CI: 111, 120) in men and 232 (213, 248) in 316 women (43.6% and 60.8% reduction respectively).

317 Changing the prioritisation thresholds so that the total number of events identified after 318 prioritisation was 63.5% and 43.4% of all events amongst men and women respectively (the 319 total number identified when the primary care records-based prioritisation tool was used 320 with conventional risk factors), prioritising using PRS resulted in a NNS of 82 (95% CI: 79, 85) in men and 223 (95% CI: 205, 240) in women and a NNI of 149 (95% CI: 143, 155) in men and 321 322 223 (95% CI: 205, 240) in women. Prioritising using PRS and primary care records resulted in 323 a NNS of 58 (95% CI: 55, 60) in men and 90 (95% CI: 83, 97) in women and a NNI of 105 (95% 324 CI: 101, 110) in men and 163 (95% CI: 151, 176) in women (Table 4, supplementary figure 4). 325 Compared to prioritising using primary care records, the reductions in the NNS and NNI 326 when prioritising using PRS and primary care records, were consistently greater in younger 327 individuals and were statistically significant at the 5% level for all age groups except in 328 women aged 40-49.

329

330 Sensitivity Analysis

In sensitivity analyses including all individuals (i.e., including 15,324 individuals without a primary care record for any one of SBP, total cholesterol, HDL cholesterol or BMI) (Supplementary table 10), we found comparable results for the PRS-based prioritisation tool and the primary care-based prioritisation tool in men and women. As expected, we observed an increase in the NNS in the prioritisation tools derived with primary care records, especially amongst the lower age group (Supplementary table 11-13, supplementary figure 5).

338

In sensitivity analyses assuming only half of those who accepted the invitation for a formal assessment and were deemed high risk complied with statin uptake, the NNS doubled for all prioritisation tools, with the NNS to prevent one event increasing to 143 in men and 805 in women when using the PRS based prioritisation tool, and 131 in men and 373 in women when using the primary care records-based prioritisation tool (**Supplementary table 14-16**, **supplementary figure 6**).

346 **DISCUSSION**

347

This study has rigorously assessed the impact of using PRS both alone and in combination 348 349 with traditional risk factors for systematically prioritising individuals for a formal CVD risk 350 assessment, and compared the efficiency and effectiveness against current 351 recommendations of using existing data on CVD risk factors within primary care records. 352 First, we found that adding PRS to both a prioritisation tool and formal CVD risk assessment model improves their correlation, which subsequently leads to higher efficiency and 353 354 effectiveness of a prioritisation tool, especially amongst younger individuals. Consequently, 355 PRS in combination with primary care records reduces the number of men and women 356 needed to be screened to prevent one CVD event (NNS) by around 20% and 35% 357 respectively, in comparison to using primary care records alone and identifying the same 358 number of events. In contrast, using the PRS alone and in place of primary care records in a prioritisation tool leads to larger NNS. These results support the use of PRS together with 359 360 primary care records to prioritise individuals at highest risk of a CVD event for a formal CVD risk assessment, which could lead to better allocation of resources by reducing the number 361 362 of formal risk assessments in primary care.

363

364 This study has provided a comparison of prioritisation tools using longitudinal primary care records and/or PRS within the UK population aged between 40 and 69 years who are 365 366 currently invited for a National Health Service (NHS) Health Check to assess their individual risk of CVD. We have demonstrated the benefits of PRS not only by measuring model 367 368 discrimination, but also by evaluating the health impact if implemented within this population. Compared with previous studies which have generally focussed on the role of 369 PRS in a formal CVD risk assessment model^{20,21,29,38}, our study has uniquely assessed its role 370 in a prioritisation tool, in conjunction with a CVD risk model. We have also shown that if PRS 371 372 were widely available, the inclusion of PRS in a prioritisation tool could improve the 373 effectiveness of a prioritisation tool especially in younger individuals by reducing the reliance on primary care records. 374

376 The benefits in prioritising a subgroup of those individuals at low absolute risk to increase 377 efficiency echoes other studies, which have also shown that selecting a smaller proportion 378 of younger, low-risk individuals can lead to dramatically reduced costs whilst resulting in more Quality Adjusted Life Years (QALYs) gained.³⁹ Using a prioritisation tool could also 379 efficiently help reduce the concerning backlog in health checks caused by the COVID-19 380 pandemic⁴⁰, where the number of people invited to health checks in England declined by 381 82% between the end of 2019 and 2020,^{41–43} while still preventing nearly the same number 382 of CVD events. Whilst the addition of PRS has the potential to prioritise individuals earlier 383 384 for a formal CVD assessment, further extensions include using PRS to identify individuals at 385 high risk of other common chronic diseases, including diabetes, dementia and kidney disease.44-48 386

387

388

389 Strengths and Limitations

Our study has several strengths. This study is the first of our knowledge to directly compare 390 391 how using different data types for a prioritisation tool can impact on the CVD risk 392 assessment programme in England. This was possible due to the unique data linkage of primary care records along with a baseline survey in UK Biobank. We derived the PRS based 393 394 prioritisation tools using two current and well documented PRS that have been shown to 395 improve model performance independent of traditional CVD risk factors. We also took 396 advantage of the sporadically observed longitudinal primary care records when deriving the 397 primary care records-based prioritisation tools, by estimating current risk factor values using a multivariate mixed model. Whilst QRISK2, which replaces missing non-recorded values 398 399 with age, sex and ethnicity-specific population average values, could have been used in our 400 study for the prioritisation tool, we chose to optimise the available longitudinal data in 401 primary care records to reduce possible over-inflation of the information from PRS. Another 402 strength of this study is the use of 10-fold cross validation to correct for over optimism that 403 may exist in our analyses as we derived and conducted the population health modelling in 404 the same individuals. Further, we used rescaling methods to adjust the 10-year risk 405 estimates for all of the models to minimise the healthy selection bias when deriving models 406 in UK Biobank.

407

408 However, several potential limitations exist. First, whilst we used primary care records that 409 were no more than six and a half years old before baseline, the mean risk factor levels 410 between primary care records and at the UKB baseline differed within the same individuals 411 which could lead to a different distribution of 10-year risk estimates. This may also weaken the correlations between the prioritisation tool and formal risk assessment models reported. 412 Second, we determined the number of events identified in the population health modelling 413 414 by calculating the model's sensitivity in UKB and translating to a hypothetical population; 415 due to the low number of events in UKB, the sensitivity of each model may be limited in 416 accuracy, especially in younger age groups with fewer events. Third, PRS for cardiovascular 417 disease are still under active development and, while we utilise two extensively studied and 418 validated PRS, there are likely more powerful PRS soon to be available⁴⁹. Finally, the age-419 range of the population health modelling was limited to between 40 and 69 years old due to 420 the use of UK Biobank. This restricts the population health modelling and in particular limits 421 the ability to investigate the early prioritisation capabilities of PRS (which are fixed at 422 conception).

423

424 Conclusion

425 Population health guidelines in England recommend individuals at higher estimated risk of 426 CVD be prioritised for formal risk assessment. Our results show that incorporating PRS 427 improves the correlation between prioritisation tools and formal CVD risk assessment 428 models. In particular, the use of PRS together with primary care records to prioritise 429 individuals at highest risk of a CVD event for a formal CVD risk assessment has the ability to efficiently prioritise those who need interventions the most, which could lead to better 430 431 allocation of resources by reducing the number of formal risk assessments in primary care.

432

DECLARATIONS 433

Acknowledgements 434

435 CPRD uses data provided by patients and collected by the NHS as part of their care and support. This work was supported by Health Data Research UK, which is funded by the UK 436 437 Medical Research Council, Engineering and Physical Sciences Research Council, Economic 438 and Social Research Council, Department of Health and Social Care (England), Chief Scientist

439 Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency 440 441 (Northern Ireland), British Heart Foundation and Wellcome. For the purpose of open access, 442 the author has applied a Creative Commons Attribution (CC BY) licence to any Author 443 Accepted Manuscript version arising from this submission. This work was performed using 444 resources provided by the Cambridge Service for Data Driven Discovery (CSD3) operated by 445 the University of Cambridge Research Computing Service (<u>www.csd3.cam.ac.uk</u>), provided by Dell EMC and Intel using Tier-2 funding from the Engineering and Physical Sciences 446 447 Research Council (capital grant EP/P020259/1), and DiRAC funding from the Science and 448 Technology Facilities Council (<u>www.dirac.ac.uk</u>).

449

450 Funding

This work was supported by core funding from the: British Heart Foundation (RG/13/13/30194; RG/18/13/33946), BHF Cambridge Centre of Research Excellence (RE/13/6/30180) and NIHR Cambridge Biomedical Research Centre (BRC-1215-20014) [*]. *The views expressed are those of the author(s) and not necessarily those of the NIHR, NHSBT or the Department of Health and Social Care.

456

457 This work was funded by the Medical Research Council (MR/K014811/1). The study funders played no role in the design, analysis or interpretation of the study. R.C. is funded by a BHF 458 459 PhD studentship (FS/18/56/34177). Z.X. is funded by the Chinese Scholarship Council. M.A. was funded by a British Heart Foundation Programme Grant (RG/18/13/33946). S.I. was 460 funded by a BHF-Turing Cardiovascular Data Science Award (BCDSA\100005) and is funded 461 462 by a University College London FB Cancer Research UK Award (C18081/A31373). H.H. is 463 funded by an International Alliance for Cancer Early Detection Project Award (ACEDFR3 06201135PR007). J.B. was funded by a Medical Research Council fellowship 464 (MR/L501566/1) and unit programme (MC_UU_00002/5). L.P. is funded by a British Heart 465 Foundation Programme Grant (RG/18/13/33946). L.G.K. was funded by the NIHR BTRU in 466 Donor Health and Genomics (NIHR BTRU-2014–10024) and is funded by the NIHR BTRU in 467 Donor Health and Behaviour (NIHR203337) [*]. M.I. is supported by the Munz Chair of 468 469 Cardiovascular Prediction and Prevention and the NIHR Cambridge Biomedical Research 470 Centre (BRC-1215-20014) and EU Horizon 2020 (No 101016775 INTERVENE). M.I. was also

471 supported by the UK Economic and Social Research 878 Council (ES/T013192/1). J.A.U. is
472 funded by an NIHR Advanced Fellowship (NIHR300861). A.M.W. is part of the
473 BigData@Heart Consortium, funded by the Innovative Medicines Initiative-2 Joint
474 Undertaking under grant agreement No 116074. A.M.W. is supported by the BHF-Turing
475 Cardiovascular Data Science Award (BCDSA\100005).

476

477 Author contributions

- R.C., J.A.U. and A.M.W. designed the study. R.C., Z.X., M.A. and A.M.W. were involved in
 data preparation. R.C., Z.X., M.A., L.P., M.I. and A.M.W were involved with the methodology.
 R.C., Z.X. and A.M.W. conducted the statistical analysis. R.C. and A.M.W. wrote the first
 version of the manuscript. All authors reviewed and edited the manuscript.
- 482

483 **Ethics approval**

- This research has been conducted using the UK Biobank Resource under Application Number 26865. Data from the Clinical Practice Research Datalink (CPRD) were obtained under licence from the UK Medicines and Healthcare products Regulatory Agency (protocol 162RMn2).
- 488

489 Data availability

- 490 All data files are available from the UK Biobank and CPRD databases.
- 491

492 Transparency

- 493 The lead author (RC) affirms that the manuscript is an honest, accurate, and transparent
- 494 account of the study being reported; that no important aspects of the study have been
- 495 omitted; and that any discrepancies from the study as planned (and, if relevant, registered)
- 496 have been explained.

497

498 Conflict of interest

499 During the drafting of the manuscript, M.A. became an employee of AstraZeneca.

503 1. Roth GA, Johnson C, Abajobir A, Abd-Allah F, Abera SF, Abyu G, Ahmed M, Aksut B, 504 Alam T, Alam K, et al. Global, Regional, and National Burden of Cardiovascular Diseases for 505 10 Causes, 1990 to 2015. J. Am. Coll. Cardiol. [Internet]. 2017 [cited 2019 Aug 12];70:1–25. 506 Available from: http://www.ncbi.nlm.nih.gov/pubmed/28527533 507 2. Wallace ML, Ricco JA, Barrett B. Screening strategies for cardiovascular disease in asymptomatic adults [Internet]. Prim. Care - Clin. Off. Pract. 2014 [cited 2021 Jan 508 509 15];41:371–397. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4042912/ 510 511 3. Siontis GCM, Tzoulaki I, Siontis KC, Ioannidis JPA. Comparisons of established risk 512 prediction models for cardiovascular disease: Systematic review. BMJ [Internet]. 2012 513 [cited 2021 Jan 15];344. Available from: https://pubmed.ncbi.nlm.nih.gov/22628003/ 4. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, Minhas R, Sheikh A, Brindle P. 514 515 Predicting cardiovascular risk in England and Wales: prospective derivation and 516 validation of QRISK2. BMJ [Internet]. 2008 [cited 2021 Nov 23];336:1475–1482. 517 Available from: https://pubmed.ncbi.nlm.nih.gov/18573856/ 518 Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk 5. 519 prediction algorithms to estimate future risk of cardiovascular disease: Prospective cohort study. BMJ [Internet]. 2017 [cited 2021 Jan 18];357. Available from: 520 521 http://www.bmj.com/ 522 Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney MT, Corrà 6. 523 U, Cosyns B, Deaton C, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice. The Sixth Joint Task Force of the European Society of 524 Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical 525 526 Practice (constituted by representatives of 10 societies and by invited experts. 527 Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation. G. Ital. Cardiol. (Rome). 2017;18:547-612. 528 7. Anderson TJ, Gr J, Pearson GJ, Barry AR, Couture P, Dawes M, Francis GA, Genest J, 529 Grover S, Gupta M, et al. 2016 Canadian Cardiovascular Society Guidelines for the 530 Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the 531 Adult. Can. J. Cardiol. [Internet]. 2016 [cited 2020 May 13];32:1263–1282. Available 532 from: http://dx.doi.org/10.1016/j.cjca.2016.07.5100828-282X/Ó 533 534 8. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ,

Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, et al. 2019 ACC/AHA Guideline
on the Primary Prevention of Cardiovascular Disease: A Report of the American
College of Cardiology/American Heart Association Task Force on Clinical Practice
Guidelines. *Circulation*. 2019;140:e596–e646.

- 539 9. D'Agostino RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB.
 540 General cardiovascular risk profile for use in primary care: The Framingham heart
 541 study. *Circulation* [Internet]. 2008 [cited 2021 Jan 19];117:743–753. Available from:
 542 https://pubmed.ncbi.nlm.nih.gov/18212285/
- 543 10. Deanfield J, Sattar N, Simpson I, Wood D, Bradbury K, Fox K, Boon N, Winocour P,
 544 Feher M, Doherty P, et al. Joint British Societies' consensus recommendations for the
 545 prevention of cardiovascular disease (JBS3) [Internet]. Heart. 2014 [cited 2020 Jul
- 546 1];100:ii1–ii67. Available from: https://heart.bmj.com/content/100/Suppl_2/ii1
- Larsen LB, Sondergaard J, Thomsen JL, Halling A, Sønderlund AL, Christensen JR,
 Thilsing T. Step-wise approach to prevention of chronic diseases in the Danish
 primary care sector with the use of a personal digital health profile and targeted
- follow-up- A n assessment of attendance. *BMC Public Health* [Internet]. 2019 [cited
 2020 Oct 20];19:1092. Available from:

552 https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-019-7419-4

Krogsbøll LT, Jørgensen KJ, Grønhøj Larsen C, Gøtzsche PC. General health checks in
adults for reducing morbidity and mortality from disease: Cochrane systematic review
and meta-analysis. *BMJ* [Internet]. 2012 [cited 2021 Jan 17];345. Available from:

556 http://www.bmj.com/content/345/bmj.e7191?tab=related#webextra

- 13. Kypridemos C, Allen K, Hickey GL, Guzman-Castillo M, Bandosz P, Buchan I, Capewell S,
 O'Flaherty M. Cardiovascular screening to reduce the burden from cardiovascular
- disease: Microsimulation study to quantify policy options. *BMJ* [Internet]. 2016 [cited
- 560
 2021 Jan 17];353. Available from: http://dx.doi.org/10.1136/bmj.i2793
- 561 14. Si S, Moss JR, Sullivan TR, Newton SS, Stocks NP. Effectiveness of general practice-
- based health checks: A systematic review and meta-analysis [Internet]. Br. J. Gen.
- 563 Pract. 2014 [cited 2020 Oct 27];64:e47–e53. Available from:

564 https://bjgp.org/content/64/618/e47

565 15. Capewell S, McCartney M, Holland W. Invited debate: NHS Health Checks--a naked
566 emperor? *J. Public Health (Bangkok)*. [Internet]. 2015 [cited 2021 Jan 18];37:187–192.

Available from: https://academic.oup.com/jpubhealth/article-567 lookup/doi/10.1093/pubmed/fdv063 568 569 16. Forster AS, Burgess C, Dodhia H, Fuller F, Miller J, McDermott L, Gulliford MC. Do 570 health checks improve risk factor detection in primary care? Matched cohort study using electronic health records. J. Public Health (Bangkok). [Internet]. 2016 [cited 571 572 2021 Jan 18];38:552–559. Available from: https://academic.oup.com/jpubhealth/article-lookup/doi/10.1093/pubmed/fdv119 573 Robson J, Dostal I, Madurasinghe V, Sheikh A, Hull S, Boomla K, Griffiths C, Eldridge S. 574 17. 575 NHS Health Check comorbidity and management: An observational matched study in 576 primary care. Br. J. Gen. Pract. [Internet]. 2017 [cited 2021 Jan 18];67:e86–e93. 577 Available from: https://doi.org/10.3399/bjgp16X688837 578 National Institute for Health and Care Excellence (NICE). Lipid modification: 18. 579 Cardiovascular risk assessment and the modification of blood lipids for the primary 580 and secondary prevention of cardiovascular disease (clinical guideline CG181). 2014; 581 19. Abraham G, Havulinna AS, Bhalala OG, Byars SG, De Livera AM, Yetukuri L, Tikkanen E, 582 Perola M, Schunkert H, Sijbrands EJ, et al. Genomic prediction of coronary heart 583 disease. Eur. Heart J. [Internet]. 2016 [cited 2019 Aug 12];37:3267-3278. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27655226 584 585 20. Inouye M, Abraham G, Nelson CP, Wood AM, Sweeting MJ, Dudbridge F, Lai FY, Kaptoge S, Brozynska M, Wang T, et al. Genomic Risk Prediction of Coronary Artery 586 587 Disease in 480,000 Adults: Implications for Primary Prevention. J. Am. Coll. Cardiol. 2018;72:1883-1893. 588 Sun L, Pennells L, Kaptoge S, Nelson CP, Ritchie SC, Abraham G, Arnold M, Bell S, 589 21. 590 Bolton T, Burgess S, et al. Polygenic risk scores in cardiovascular risk prediction: A cohort study and modelling analyses. PLOS Med. [Internet]. 2021 [cited 2021 Jan 591 592 17];18:e1003498. Available from: https://dx.plos.org/10.1371/journal.pmed.1003498 Paige E, Barrett J, Pennells L, Sweeting M, Willeit P, Angelantonio E Di, Gudnason V, 593 22. Nordestgaard BG, Psaty BM, Goldbourt U, et al. Use of Repeated Blood Pressure and 594 Cholesterol Measurements to Improve Cardiovascular Disease Risk Prediction: An 595 Individual-Participant-Data Meta-Analysis. Am. J. Epidemiol. 2017;186:899. 596 597 Paige E, Barrett J, Stevens D, Keogh RH, Sweeting MJ, Nazareth I, Petersen I, Wood 23. 598 AM. Landmark Models for Optimizing the Use of Repeated Measurements of Risk

599		Factors in Electronic Health Records to Predict Future Disease Risk. Am. J. Epidemiol.
600		[Internet]. 2018 [cited 2021 Nov 23];187:1530–1538. Available from:
601		https://academic.oup.com/aje/article/187/7/1530/4952104
602	24.	Arruda-Olson AM, Afzal N, Priya Mallipeddi V, Said A, Moussa Pacha H, Moon S,
603		Chaudhry AP, Scott CG, Bailey KR, Rooke TW, et al. Leveraging the Electronic Health
604		Record to Create an Automated Real-Time Prognostic Tool for Peripheral Arterial
605		Disease. J. Am. Heart Assoc. [Internet]. 2018 [cited 2020 May 26];7:e009680.
606		Available from: http://www.ncbi.nlm.nih.gov/pubmed/30571601
607	25.	Barrett JK, Sweeting MJ, Wood AM. Dynamic Risk Prediction for Cardiovascular
608		Disease: An Illustration Using the ARIC Study. In: Handbook of Statistics. Elsevier B.V.;
609		2017. p. 47–65.
610	26.	Sweeting MJ, Barrett JK, Thompson SG, Wood AM. The use of repeated blood
611		pressure measures for cardiovascular risk prediction: a comparison of statistical
612		models in the ARIC study. Stat. Med. [Internet]. 2017 [cited 2019 Dec 27];36:4514-
613		4528. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27730661
614	27.	Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, Motyer A, Vukcevic D,
615		Delaneau O, O'Connell J, et al. The UK Biobank resource with deep phenotyping and
616		genomic data. Nature [Internet]. 2018 [cited 2022 Jul 22];562:203–209. Available
617		from: https://pubmed.ncbi.nlm.nih.gov/30305743/
618	28.	Herrett E, Gallagher AM, Bhaskaran K, Forbes H, Mathur R, Staa T van, Smeeth L. Data
619		Resource Profile: Clinical Practice Research Datalink (CPRD). Int. J. Epidemiol.
620		2015;44:827–836.
621	29.	Abraham G, Malik R, Yonova-Doing E, Salim A, Wang T, Danesh J, Butterworth AS,
622		Howson JMM, Inouye M, Dichgans M. Genomic risk score offers predictive
623		performance comparable to clinical risk factors for ischaemic stroke. Nat. Commun.
624		2019 101 [Internet]. 2019 [cited 2022 Jan 17];10:1–10. Available from:
625		https://www.nature.com/articles/s41467-019-13848-1
626	30.	Pennells L, Kaptoge S, Wood A, Sweeting M, Zhao X, White I, Burgess S, Willeit P,
627		Bolton T, Moons KGM, et al. Equalization of four cardiovascular risk algorithms after
628		systematic recalibration: Individual-participant meta-analysis of 86 prospective
629		studies. <i>Eur. Heart J.</i> 2019;40:621–631.

630 31. Kaptoge S, Pennells L, De Bacquer D, Cooney MT, Kavousi M, Stevens G, Riley LM,

Savin S, Khan T, Altay S, et al. World Health Organization cardiovascular disease risk

631

632 charts: revised models to estimate risk in 21 global regions. Lancet Glob. Heal. 633 2019;7:e1332-e1345. 634 32. Office for National Statistics. Estimates of the population for the UK, England and 635 Wales, Scotland and Northern Ireland [Internet]. [cited 2022 Jan 17]; Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/p 636 637 opulationestimates/datasets/populationestimatesforukenglandandwalesscotlandand northernireland 638 639 33. Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, Voysey M, Gray A, 640 Collins R, Baigent C, et al. The effects of lowering LDL cholesterol with statin therapy 641 in people at low risk of vascular disease: Meta-analysis of individual data from 27 642 randomised trials. Lancet [Internet]. 2012 [cited 2021 Nov 23];380:581–590. Available 643 from: http://www.thelancet.com/article/S0140673612603675/fulltext 644 34. Cook NR, Ridker P. Further insight into the cardiovascular risk calculator: the roles of 645 statins, revascularizations, and underascertainment in the Women's Health Study. 646 JAMA Intern. Med. [Internet]. 2014 [cited 2022 Feb 17];174:1964–1971. Available 647 from: https://pubmed.ncbi.nlm.nih.gov/25285455/ Patel R, Barnard S, Thompson K, Lagord C, Clegg E, Worrall R, Evans T, Carter S, 648 35. 649 Flowers J, Roberts D, et al. Evaluation of the uptake and delivery of the NHS Health Check programme in England, using primary care data from 9.5 million people: A 650 651 cross-sectional study. BMJ Open [Internet]. 2020 [cited 2021 Jan 14];10:42963. Available from: http://bmjopen.bmj.com/ 652 Martin A, Saunders CL, Harte E, Griffin SJ, MacLure C, Mant J, Meads C, Walter FM, 653 36. 654 Usher-Smith JA. Delivery and impact of the NHS Health Check in the first 8 years: A 655 systematic review. Br. J. Gen. Pract. [Internet]. 2018 [cited 2020 Oct 27];68:e449e459. Available from: /pmc/articles/PMC6014431/?report=abstract 656 Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Peteresen I, Sørensen HT, 657 37. von Elm E, Langan SM. The REporting of studies Conducted using Observational 658 Routinely-collected health Data (RECORD) Statement. PLOS Med. [Internet]. 2015 659 [cited 2021 Nov 23];12:e1001885. Available from: 660 https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1001885 661 662 38. Riveros-Mckay F, Weale ME, Moore R, Selzam S, Krapohl E, Sivley RM, Tarran WA,

663		Sørensen P, Lachapelle AS, Griffiths JA, et al. Integrated Polygenic Tool Substantially
664		Enhances Coronary Artery Disease Prediction. Circ. Genomic Precis. Med. [Internet].
665		2021 [cited 2022 Aug 23];14:E003304. Available from:
666		https://www.ahajournals.org/doi/abs/10.1161/CIRCGEN.120.003304
667	39.	Crossan C, Lord J, Ryan R, Nherera L, Marshall T. Cost effectiveness of case-finding
668		strategies for primary prevention of cardiovascular disease: A modelling study. Br. J.
669		Gen. Pract. [Internet]. 2017 [cited 2021 Apr 7];67:e67–e77. Available from:
670		https://bjgp.org/content/67/654/e67
671	40.	Public Health England. NHS Health Check - Data - OHID [Internet]. [cited 2022 Feb
672		15];Available from: https://fingertips.phe.org.uk/profile/nhs-health-check-
673		detailed/data#page/4/gid/1938132726/pat/159/par/K02000001/ati/15/are/E920000
674		01/iid/91733/age/219/sex/4/cat/-1/ctp/-1/yrr/1/cid/4/tbm/1
675	41.	Health and Social Care Committee. Clearing the backlog caused by the pandemic
676		[Internet]. [cited 2022 Feb 15];Available from:
677		https://publications.parliament.uk/pa/cm5802/cmselect/cmhealth/599/report.html
678	42.	lacobucci G. Covid-19: Government must fund extra NHS capacity to tackle backlog,
679		BMA urges. BMJ [Internet]. 2020 [cited 2022 Feb 15];370:m3587. Available from:
680		https://www.bmj.com/content/370/bmj.m3587
681	43.	Levene LS, Seidu S, Greenhalgh T, Khunti K. Pandemic threatens primary care for long
682		term conditions. BMJ [Internet]. 2020 [cited 2022 Feb 15];371. Available from:
683		https://www.bmj.com/content/371/bmj.m3793
684	44.	Padilla-Martínez F, Collin F, Kwasniewski M, Kretowski A. Systematic Review of
685		Polygenic Risk Scores for Type 1 and Type 2 Diabetes. Int. J. Mol. Sci. [Internet]. 2020
686		[cited 2022 Aug 23];21. Available from: /pmc/articles/PMC7084489/
687	45.	Najar J, van der Lee SJ, Joas E, Wetterberg H, Hardy J, Guerreiro R, Bras J, Waern M,
688		Kern S, Zetterberg H, et al. Polygenic risk scores for Alzheimer's disease are related to
689		dementia risk in APOE ɛ4 negatives. Alzheimer's Dement. Diagnosis, Assess. Dis.
690		Monit. [Internet]. 2021 [cited 2022 Aug 23];13. Available from:
691		/pmc/articles/PMC7821873/
692	46.	Chaudhury S, Brookes KJ, Patel T, Fallows A, Guetta-Baranes T, Turton JC, Guerreiro R,
693		Bras J, Hardy J, Francis PT, et al. Alzheimer's disease polygenic risk score as a

694 predictor of conversion from mild-cognitive impairment. *Transl. Psychiatry 2019 91*

695 [Internet]. 2019 [cited 2022 Aug 23];9:1–7. Available from: 696 https://www.nature.com/articles/s41398-019-0485-7 697 47. Leonenko G, Baker E, Stevenson-Hoare J, Sierksma A, Fiers M, Williams J, de Strooper 698 B, Escott-Price V. Identifying individuals with high risk of Alzheimer's disease using polygenic risk scores. Nat. Commun. 2021 121 [Internet]. 2021 [cited 2022 Aug 699 700 23];12:1–10. Available from: https://www.nature.com/articles/s41467-021-24082-z 701 48. Hirohama D, Susztak K. From mapping kidney function to mechanism and prediction. 702 Nat. Rev. Nephrol. 2021 182 [Internet]. 2021 [cited 2022 Aug 23];18:76–77. Available from: https://www.nature.com/articles/s41581-021-00512-5 703 704 49. Mishra A, Malik R, Hachiya T, Jürgenson T, Namba S, Posner DC, Kamanu FK, Koido M, 705 Le Grand Q, Shi M, et al. Stroke genetics informs drug discovery and risk prediction 706 across ancestries. Nat. 2022 [Internet]. 2022 [cited 2022 Oct 6];1–15. Available from: https://www.nature.com/articles/s41586-022-05165-3 707

Characteristic	Men, N = 44	l,184 (41%)	Women, N = 64,501 (59%)			
CVD events, N	123	30	608			
Follow up duration: years, median (5 th , 95 th percentile)	8.1 (6.1, 10.8)		8.2 (6.8, 10.9)			
Duration between first primary care record and baseline visit:	26/00					
years, median (5 th , 95 th percentile)	5.0 (0.:	5, 5.5]	5.9 (1.1, 5.0)			
	Primary care records	Baseline	Primary care records	Baseline		
Age, mean (SD) ^a	-	56.2 (8.0)	-	56.1 (7.8)		
Coronary artery disease PRS, mean (SD)	-	-1.15 (0.46)	-	-1.13 (0.46)		
Stroke PRS, mean (SD)	-	1.55 (0.22)	-	1.56 (0.23)		
Ethnicity — White, N (%) ^a	-	42,283 (95.7%)	-	61,977 (96.1%)		
Townsend, mean (SD) ^a	-	-1.5 (3.0)	-	-1.5 (2.9)		
Systolic blood pressure:						
mmHg, mean (SD) ^b	135.3 (7.82)	141.0 (17.3)	130.7 (9.62)	134.9 (19.1)		
Number of historical records, mean	3.8	-	4.6	-		
Total cholesterol:						
mmol/litre, mean (SD) ^b	5.48 (0.47)	5.79 (1.01)	5.71 (0.50)	6.03 (1.08)		
Number of historical records, mean	2.0	-	2.0	-		
HDL cholesterol:						
mmol/litre, mean (SD) ^b	1.35 (0.19)	1.30 (0.31)	1.68 (0.24)	1.61 (0.37)		
Number of historical records, mean	1.8	-	1.9	-		
BMI:						
kg/m2, mean (SD) ^b	27.2 (3.1)	27.5 (4.1)	26.6 (4.1)	26.8 (5.0)		
Number of historical records, mean	2.0	-	2.3	-		
Current smoker, N (%)	4,472 (10.1%)	5,233 (11.8%)	4,911 (7.61%)	5,511 (8.5%)		
History of diabetes, N (%)	466 (1.05%)	630 (1.4%)	412 (0.64%)	459 (0.7%)		
Blood pressure-lowering medication prescriptions, N (%)	6,396 (14.5%)	5,529 (12.51%)	9,737 (15.1%)	7,643 (11.85%)		
Family history, N (%) ^a	1,568 (3.55%)	-	2,494 (3.87%)	-		
Chronic kidney disease (4/5), N (%) ^a	57 (0.13%)	-	79 (0.12%)	-		
Rheumatoid arthritis, N (%)	146 (0.33%)	381 (0.86%)	336 (0.52%)	989 (1.53%)		
Atrial fibrillation, N (%)	336 (0.33%)	123 (0.28%)	1,749 (2.7%)	89 (0.14%)		

Table 1: Key characteristics of individuals in UK Biobank baseline survey and linked primary care records

Abbreviations: BMI, body mass index; CVD, cardiovascular disease; HDL cholesterol, high-density lipoprotein cholesterol; PRS, polygenic risk score; SD, standard deviation.

^a Risk factor values in both baseline and primary care records if one was missing.

^b Risk factor values for primary care records estimated using multivariate mixed effects model.

Model	C-index (95% confidence interval)						
	All individuals	Men	Women				
Prioritisation tool							
Primary care records	0.730 (0.719, 0.741)	0.684 (0.670, 0.699)	0.734 (0.715, 0.754)				
only							
PRS + age	0.663 (0.652, 0.675)	0.663 (0.649, 0.678)	0.686 (0.665, 0.707)				
PRS + primary care	0.740 (0.730, 0.751)	0.704 (0.691, 0.718)	0.738 (0.718, 0.758)				
records							
Formal risk assessment tool							
Conventional risk	0.730 (0.719, 0.740)	0.700 (0.686, 0.714)	0.739 (0.720, 0.759)				
factors							
Conventional risk	0.738 (0.727, 0.749)	0.716 (0.702, 0.730)	0.742 (0.722, 0.762)				
factors +PRS							

Table 2: C indices of prioritisation tools and formal CVD risk assessment tools in UK Biobank

Abbreviations: PRS, polygenic risk score.

C indices and 95% confidence intervals from each model for the prediction of 10-year cardiovascular disease by sex and for the combined population in UK Biobank after 10-fold cross validation.

Table 3: Correlation of predicted 10-year risks between prioritisation tools and formal assessment tools by sex in the derivation dataset

Men	Primary care records only prioritisation tool	PRS + age prioritisation tool	PRS + primary care records prioritisation tool		
Conventional risk					
factor formal	0.75	-	-		
assessment tool					
Conventional risk					
factor + PRS formal	-	0.67	0.82		
assessment tool					
Women					
Conventional risk					
factor formal	0.80	-	-		
assessment tool					
Conventional risk					
factor + PRS formal	-	0.67	0.82		
assessment tool					

Abbreviations: PRS, polygenic risk score.

Table 4: Number needed to invite and screen to prevent one event and number of events identified after prioritisation and formal assessment in a hypothetical population of 100,000 individuals in England, with prioritisation thresholds selected to identify the same number of events if prioritising with primary care records with prioritisation thresholds controlling the false negative rate to 5%.

		Prioritisation using primary care records followed by conventional risk						Prioritisation using PRS and primary care records, followed by					
		factors				Prioritisation using PRS + age, followed by conventional risk factors + PRS			conventional risk factors + PRS				
					Number of				Number of				Number of
					events				events				events
		Participants			identified as	Participants			identified as	Participants			identified as
Age		prioritised			high risk	prioritised			high risk	prioritised			high risk
group	Participants	(%)	NNI (95% CI)	NNS (95% CI)	(%)	(%)	NNI (95% CI)	NNS (95% CI)	(%)	(%)	NNI (95% CI)	NNS (95% CI)	(%)
Men													
40-49	18253	10126 (55.5%)	765 (498.9, 932.8)	421 (274.4, 513.0)	120 (24.8%)	13016 (71.3%)	727 (530.4, 856.5)	400 (291.7, 471.1)	163 (33.6%)	7208 (39.5%)	369 (265.8, 438.4)	203 (146.2, 241.1)	163 (33.6%)
50-59	17391	12134 (69.8%)	170 (150.6, 184.2)	93 (82.8, 101.3)	651 (52.5%)	13100 (75.3%)	179 (162.6, 193.3)	98 (89.4, 106.3)	666 (53.7%)	9878 (56.8%)	133 (118.4, 144.4)	73 (65.1, 79.4)	654 (52.7%)
60-69	14356	12517 (87.2%)	73 (70.4, 74.9)	40 (38.7, 41.2)	1564 (84.7%)	12196 (84.9%)	74 (70.8, 76.1)	40 (39.0, 41.9)	1506 (81.5%)	11064 (77.1%)	65 (62.1, 66.9)	36 (34.2, 36.8)	1519 (82.3%)
Total	50000	34777 (69.6%)	135 (130.4, 140.5)	74 (71.7, 77.3)	2335 (65.3%)	38313 (76.6%)	149 (143.0, 154.9)	82 (78.7, 85.2)	2335 (65.4%)	28150 (56.3%)	105 (100.5, 109.5)	58 (55.3, 60.2)	2336 (65.4%)
Women													
40-49	18107	3233 (17.9%)	1092 (0.0, 1596.1)	601 (0.0, 877.9)	27 (10.0%)	10139 (56.0%)	3550 (0.0, 5198.6)	1952 (0.0, 2859.2)	27 (10.0%)	1748 (9.7%)	506 (0.0, 731.1)	279 (0.0, 402.1)	31 (11.7%)
50-59	17282	8329 (48.2%)	572 (389.4, 701.7)	314 (214.2, 385.9)	132 (23.0%)	12436 (72.0%)	742 (507.0, 891.7)	408 (278.8, 490.4)	156 (27.1%)	4683 (27.1%)	306 (198.7, 373.0)	168 (109.3, 205.2)	139 (24.1%)
60-69	14611	10459 (71.6%)	152 (138.7, 162.1)	84 (76.3, 89.1)	626 (65.1%)	11357 (77.7%)	178 (163.2, 189.7)	98 (89.8, 104.3)	603 (62.7%)	7714 (52.8%)	114 (105.2, 121.2)	63 (57.9, 66.7)	616 (64.0%)
Total	50000	22021 (44.0%)	255 (235.4, 273.5)	140 (129.5, 150.4)	785 (43.4%)	33932 (67.9%)	406 (372.3, 436.0)	223 (204.8, 239.8)	786 (43.5%)	14145 (28.3%)	163 (150.5, 175.5)	90 (82.8, 96.5)	786 (43.5%)

Abbreviations: NNS, number needed to screen; PRS, polygenic risk score.

Age structure of hypothetical population extrapolated from Office for National Statistics, England, United Kingdom 2015. Expected events at 10 years based on extrapolation of incidence rates from CPRD, 2014-2019. Age group and sex specific prioritisation thresholds when prioritising using primary care records were defined as the level such that the expected false negative rate is controlled to be 5%. Age group and sex specific prioritisation thresholds when prioritising using PRS or PRS and primary care records tool chose thresholds that resulted in a similar number of events identified if prioritising using primary care records. Prioritisation thresholds for the PRS prioritisation tool was equivalent to a 5.9% and 6.5% false negative rate for men and women respectively, and for the PRS and primary care records prioritisation tool was equivalent to an 8.1% and 13.0% false negative rate respectively. NNI and NNS assumes 100% statin compliance. NNI assumes a 50% invitation uptake if assessing without using prioritisation tool.

Figure 1: Flow chart of the implementation of a prioritisation tool for formal cardiovascular disease assessments



Abbreviations: BMI, body mass index; CAD, coronary artery disease; CVD; cardiovascular disease; HDL, high density lipoprotein; PRS, polygenic risk score.

Figure 2: Number needed to invite, number needed to screen and number of events identified after prioritising for a formal CVD assessment, in a hypothetical population of 100,000 individuals in England.



- Prioritisation with primary care records + PRS & formal assessment with conventional risk factors + PRS

Abbreviations: NNS, number needed to screen; NNI, number needed to invite; PRS, polygenic risk score.

Men

95% confidence intervals are represented by vertical lines. Age group and sex specific prioritisation thresholds were defined as the level such that the expected false negative rate is controlled to be 5%. NNI and NNS assumes 100% statin compliance, and half of all individuals invited for formal assessment attend.